Pfizer voluntarily withdrew Oxbryta (voxelotor), a sickle cell disease drug it acquired from Global Blood Therapeutics, from all global markets on September 25, 2024, after post-marketing studies showed mortality imbalances and increased vaso-occlusive crisis rates versus placebo. The resulting litigation now runs through the Northern District of California, anchoring a coordinated docket of consumer class and personal injury claims against Pfizer and GBT.
This article examines the withdrawal record, procedural structure, preemption defense, causation issues, and what practitioners should be tracking ahead of the November 2026 fact discovery close.
The Oxbryta Withdrawal and the GBT Acquisition
Global Blood Therapeutics developed voxelotor and secured FDA approval in November 2019 for sickle cell disease in adults and children 12 years and older. Pfizer acquired GBT on October 5, 2022, for $5.4 billion, assuming safety obligations for a drug that had been on the market for three years. That acquisition timeline matters because plaintiffs frame liability around both GBT's pre-acquisition development decisions and Pfizer's post-acquisition safety obligations during the period leading to withdrawal.
Less than two years after the acquisition closed, the safety picture inverted. Pfizer withdrew all lots of Oxbryta from worldwide markets on September 25, 2024, stating that the benefit no longer outweighed the risks. The FDA issued its safety alert the following day. The European Medicines Agency had already initiated an Article 20 referral review in July 2024 over higher-than-anticipated deaths in clinical studies.
In GBT440-032, GBT440-042, and PROSPECT, the post-marketing safety record diverged sharply from the registration record:
- In study GBT440-032 (HOPE Kids 2), a pediatric stroke-risk study enrolling children aged 2 to 15, eight deaths occurred in the treatment arm compared to two in the placebo arm, with several fatal cases involving infection such as malaria or sepsis.
- In study GBT440-042 (RESOLVE), which assessed leg ulcer treatment in 88 patients aged 12 and older, the EMA assessment reported eight deaths in the open-label phase, a total the agency described as higher than anticipated.
- EMA interim data showed VOCs per patient-year of 0.49 before Oxbryta initiation and 2.71 after, a more than five-fold increase.
Plaintiffs' failure-to-warn theory relies on the post-marketing signals and the allegation that Pfizer and GBT did not adequately disclose emerging mortality and VOC risks. Defense counsel frames the same chronology differently: the withdrawal followed evolving evidence in a population already at risk for VOCs, stroke, infection, and premature death.
A No-MDL Hybrid Docket in the Northern District of California
The Oxbryta litigation departs from the typical mass tort template: there is no multidistrict litigation. The JPML's January 2026 report of pending MDLs does not list Oxbryta, and no JPML docket number has been assigned. Federal cases proceed through local coordination under Judge Trina L. Thompson in the Northern District of California, which changes leverage for both sides. A centralized MDL creates a single forum for common discovery, leadership appointments, bellwether sequencing, and settlement architecture; the Oxbryta docket depends instead on district-level coordination and private discovery agreements.
Allen v. Global Blood Therapeutics, Inc. et al., No. 3:24-cv-07786 (N.D. Cal. filed Nov. 7, 2024), alleges physical injuries including vaso-occlusive crises, stroke, and death. Jolly et al. v. Global Blood Therapeutics, Inc. et al., No. 3:24-cv-09345 (N.D. Cal. filed Dec. 23, 2024), is a consumer class action seeking reimbursement for out-of-pocket expenses, premised on allegations that Pfizer and GBT knew of Oxbryta's risks and failed to disclose them.
Because there is no MDL:
- Discovery coordination is achievable among the N.D. Cal. cases through Judge Thompson's orders, but those orders bind only cases on her docket.
- Cases in other federal districts or state court are not subject to automatic transfer or stay, so cross-jurisdictional discovery sharing depends on private negotiation.
- Plaintiff leadership has less formal control over parallel filings, which may complicate common deposition planning and expert sequencing.
- Defense counsel may face overlapping discovery demands unless protective orders, document repositories, and deposition protocols are negotiated early.
This hybrid structure concentrates oversight in the class mechanism. With no MDL, the Jolly class certification process becomes the primary structural check on settlement fairness across the docket, a dynamic that elevates the Jolly preemption ruling's importance beyond its own docket.
No Public Verdict and the Pending Preemption Motion
No verdict has been entered in the Oxbryta litigation. The most important near-term outcome is the ruling on Pfizer and GBT's motion to dismiss the First Amended Complaint in Jolly on federal preemption grounds. Plaintiffs oppose dismissal, arguing defendants have not met their burden of proving by clear evidence that the FDA would have rejected stronger warnings.
That ruling matters because it can narrow the case before document production reaches the core safety file. A defense win reduces warning-based exposure and potentially reshapes the consumer reimbursement theory. A plaintiff win opens internal safety reviews, adverse-event communications, regulatory submissions, and the full chronology of what Pfizer and GBT knew after the acquisition closed.
For valuation, the absence of a verdict leaves neither side with a reliable damages anchor. Settlement analysis will likely turn on four practical inputs:
- whether warning claims survive preemption;
- how the court treats class-wide reimbursement theories;
- whether individual injury claims can be separated from baseline SCD complications; and
- whether internal documents support a delayed-warning narrative or a rapidly evolving safety-response narrative.
Does Wyeth v. Levine Defeat Pfizer's Preemption Defense?
The preemption ruling in Jolly is the most consequential near-term event on this docket. Not because it resolves damages, but because it determines what discovery opens. A defense win narrows warning-based exposure before document production reaches the core safety file. A plaintiff win opens internal adverse-event records, regulatory submissions, and the full chronology of what Pfizer and GBT knew after the acquisition closed.
Pfizer's defense rests on impossibility preemption: the FDA controls labeling, the company could not unilaterally change Oxbryta's warnings, and plaintiffs have not shown newly acquired information triggering the Changes Being Effected process. Under 21 C.F.R. § 314.3(b), newly acquired information must reveal risks of a different type, severity, or frequency than previously submitted to the FDA.
The controlling precedent cuts against an easy defense win. In Wyeth v. Levine, 555 U.S. 555 (2009), the Supreme Court held that a brand-name manufacturer bears responsibility for its label at all times and can strengthen warnings through the CBE pathway without prior FDA approval. Oxbryta's brand-name status places the case squarely in the Wyeth framework; the generic impossibility rules of PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011), and Mutual Pharmaceutical Co. v. Bartlett, 570 U.S. 472 (2013), do not apply. Under Merck Sharp & Dohme Corp. v. Albrecht, Pfizer must show it fully informed the FDA of the justifications for the warning state law required and that the FDA responded with a force-of-law disapproval. That is a high bar, and plaintiffs argue Pfizer has not met it.
For practitioners, three strategic pressure points follow directly from that framework:
- Albrecht makes preemption a question of law for the judge, not the jury. The ruling arrives at motion to dismiss or summary judgment, before any bellwether trial, which means case positioning and settlement authority decisions cannot wait for trial.
- The accelerated-approval pathway creates an additional vulnerability for Pfizer: the drug reached market on surrogate endpoints before confirmatory trials concluded, and plaintiffs will argue the post-marketing mortality and VOC signals constitute exactly the newly acquired information the CBE pathway was designed to capture.
- Discovery scope tracks the ruling directly. Plaintiff teams building the CBE record need the PROSPECT VOC data, trial death timelines, and internal regulatory communications tied to specific label-change opportunities; defense teams need to show FDA control over every relevant labeling decision.
Causation and Damages in the Sickle Cell Patient Class
Vaso-occlusive crises and premature death, the alleged harms in the Oxbryta litigation, are also baseline features of untreated sickle cell disease. Every plaintiff must prove drug-caused injury in excess of an individual pre-treatment baseline, a fact-intensive showing that complicates both class certification and case valuation.
Those baseline features shape damages on both sides:
- Wrongful death: Lost-earnings and life-expectancy calculations will turn on the individual decedent's medical history, and defense experts will argue any remaining life expectancy was already affected by SCD independent of Oxbryta.
- Pain and suffering: Because VOCs are both the alleged harm and the central symptom of SCD, plaintiffs must show Oxbryta caused crises above each plaintiff's documented baseline.
The population-level signal does not translate automatically to specific causation. VOC is diagnosed by clinical exclusion with no objective biomarker, and EMA documentation links some trial deaths to underlying infections rather than the drug. The PROSPECT pre-Oxbryta baseline of 0.49 VOCs per patient-year against the later post-Oxbryta rate of 2.71 is a compelling population-level signal, but both sides will contest how registry data maps onto each plaintiff's counterfactual baseline.
Plaintiff counsel should treat the pre-treatment baseline as a damages element from the outset. Medical chronologies need to isolate VOC frequency, hospitalizations, infections, stroke history, transfusion history, and medication changes before and after Oxbryta initiation. Defense counsel will press the same records from the opposite direction, focusing on disease severity before treatment and alternative explanations for each crisis or death.
What Practitioners Should Be Tracking Before November 2026
Fact discovery in the Allen v. Global Blood Therapeutics, Inc. et al. bellwether track closes in November 2026, with expert discovery running through February 2027 and the first trial set for June 7, 2027. That schedule makes the next six months the most consequential period in the litigation: the window in which internal safety documents, adverse-event records, and regulatory communications either corroborate or undercut the failure-to-warn theory before any damages anchor exists.
Three additional variables will shape how the docket develops from here:
- MDL trajectory: No MDL has been centralized, but as case volume grows, a JPML petition becomes more likely. Early-filing plaintiff firms hold a steering committee positioning advantage that disappears once MDL leadership is appointed, and firms managing Oxbryta plaintiffs should be tracking JPML filings now.
- Inclacumab failure: Inclacumab, a P-selectin inhibitor Pfizer acquired through the GBT deal, failed its pivotal Phase 3 THRIVE-131 trial in August 2025 with no significant VOC reduction versus placebo. That result adds scrutiny to the $5.4 billion acquisition and may reduce Pfizer's appetite for prolonged litigation.
- The sickle cell population as a damages class: Sickle cell disease affects a historically underserved patient population with limited treatment alternatives post-withdrawal. Chronic disability, elevated medical complexity, and the absence of a comparable replacement drug strengthen general damages arguments and complicate defense efforts to attribute harm solely to underlying disease.
The preemption ruling, the MDL question, and the November 2026 fact discovery close are three sequential inflection points that each reset leverage independently.
In Summary
The Oxbryta litigation presents a procedural structure unlike most pharmaceutical mass torts: no MDL, a preemption defense that will resolve before any trial, and a causation framework complicated by a patient population with overlapping baseline disease. The no-MDL structure means case values are being established independently, creating differentiated outcomes based on venue, theory selection, and the completeness of plaintiff-specific discovery.
For practitioners managing sickle cell plaintiffs, the evidentiary work (medical chronologies isolating VOC frequency, hospitalization records, and causation timelines against pre-treatment baselines) cannot wait for bellwether results. The November 2026 fact discovery close is the operative deadline.
For related valuation frameworks, compare these issues with settlement valuations in pharmaceutical personal injury cases.
